Marksans Pharma Limited (MARKSANS)

Loading page…

Marksans Pharma Limited (MARKSANS) · mywealthgrid

About

Marksans Pharma Limited operates in pharmaceuticals within India's healthcare sector, with a market capitalization of ₹15,091.56 Cr. Quarterly consolidated revenues range ₹720–856 Cr with operating margins of 20–29%, supported by strong capital efficiency (ROE 25.56%) and minimal leverage (D/E 0.01). The company demonstrates solid profitability and financial stability.

Face value: ₹1

Market cap

₹14,756 Cr

P/E

28.6×

P/B

4.9×

Dividend yield

0.3%

ROE

25.6%

ROCE

32.4%

Debt / equity

0.01

OPM

20.4%

EPS (TTM)

₹11.4

Book value

₹66.7

52-week high

—

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

PE multiple of 29.2 leaves limited valuation upside if near-term earnings growth falters — verify what underpins market confidence in forward earnings.
Operating margins fluctuate from 20.06% to 29.31% across recent quarters — establish whether volatility reflects temporary factors or structural cost pressures.
Consolidated revenue (typically ₹720–856 Cr) substantially exceeds standalone (₹320–361 Cr); verify profitability and operational control of consolidated entities.
Pharma sector exposure to regulatory pricing pressure and generic competition — verify company's regulatory footprint and ability to offset margin pressure.

Generated analysis · source review pending

Growth drivers

Latest operating margin of 25.56% (Jun 2026) sits above trailing average of 20.36%; sustained expansion would compound earnings.
ROE of 25.56% indicates capital deployed efficiently; reinvested earnings at this return rate can fund organic growth without added leverage.
Consolidated revenue (₹840.8 Cr, Jun 2026) substantially exceeds standalone (₹321.19 Cr); verify whether acquired or subsidiary operations can scale profitably.
Quarterly net profit consistency (₹60–159 Cr range) suggests stable cash generation for both dividends and reinvestment.

Generated analysis · source review pending

2,528 historical price candles were omitted because the exchange source has not been verified.

₹325.6-5%1Y

Quick read

rule-based

Pros

+Healthy operating margin of 20.4%
+Revenue CAGR of 16.5% over the last 5 years
+Almost debt-free (debt/equity 0)
+Comfortable interest coverage of 24.2×

Cons

−Low dividend payout of 7.9% of profit

Research score

Structured signal from quality, growth, valuation and momentum.

72/100

Business quality: 85
Growth: 80
Valuation: 50

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Part ofNIFTY MICROCAP 250 NIFTY TOTAL MARKET

Screen this industry

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	767	1,000	1,134	1,376	1,491	1,852	2,177	262	2,951
COGS	459	498	545	595	717	921	1,038	114	1,277
Gross profit	308	502	589	781	774	931	1,139	148	1,674
	264	370	397	442	515	591	681	95	1,073
	45	132	192	340	259	339	459	53	601
OPM %	5.8%	13.2%	17%	24.7%	17.4%	18.3%	21.1%	20.2%	20.4%
Depreciation	30	23	27	36	45	52	74	8	99
Interest	7	10	9	8	8	9	11	1	24
	7	5	0	7	42	59	50	7	83
Profit before tax	15	104	157	302	248	338	424	50	561
Tax	4	24	36	64	61	72	109	12	140
Tax %	23.9%	22.9%	23.2%	21.1%	24.5%	21.4%	25.7%	24.1%	25.1%
	11	80	121	239	187	265	315	38	420
PAT margin %	1.5%	8%	10.7%	17.3%	12.5%	14.3%	14.5%	14.6%	14.2%
EPS (₹)	0.2	1.9	2.9	5.8	4.5	6.4	6.9	8.4	9.2
EPS adjusted (₹)	—	—	—	5.8	4.6	5.9	7.6	8.5	9.2
	22.7%	2.7%	3.5%	4.3%	5.5%	7.8%	8.7%	9.5%	9.8%
Annual report	Annual report for Mar 2018	Annual report for Mar 2019	Annual report for Mar 2020	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	Annual report for Mar 2026

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	41	41	45	45	5	45
Reserves	846	1,161	1,700	2,020	242	2,978
Minority interest	19	21	20	21	2	30
	19	41	42	29	2	30
	305	376	384	566	73	779
Total equity & liabilities	1,229	1,640	2,190	2,681	324	3,861
	309	428	486	776	98	743
CWIP	6	1	7	5	1	15
Investments	0	0	1	27	0	0
	914	1,211	1,696	1,873	225	3,103
Total assets	1,229	1,640	2,190	2,681	324	3,861

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	50.2%	52%	56.8%	51.9%	50.3%	52.3%	56.4%	56.7%
EBITDA margin %	13.2%	17%	24.7%	17.4%	18.3%	21.1%	20.2%	20.4%
EBIT margin %	10.9%	14.6%	22.1%	14.4%	15.5%	17.6%	17%	17%
PAT margin %	8%	10.7%	17.3%	12.5%	14.3%	14.5%	14.6%	14.2%
Working capital
Receivable days	—	—	72	97	82	76	75	80
Inventory days	—	—	248	216	192	217	270	278
Payable days	—	—	—	102	91	94	98	96
NWC days	—	—	—	211	183	199	247	261
Leverage
Current ratio	—	—	3.02	3.37	4.91	4.78	4.62	5.17
Debt to EBITDA	—	—	0.06	0.16	0.12	0.06	0.04	0.05
Debt to equity	—	—	0.02	0.03	0.02	0.01	0.01	0.01
Interest coverage	11.8	19	38.8	30.3	38	38.8	44.1	24.2
Asset turnover	—	—	1.12	0.91	0.85	0.81	0.81	0.76
Return ratios
Return on assets %	—	—	19.4%	11.4%	12.1%	11.7%	11.8%	10.9%
Return on capital employed %	—	—	33.4%	23.1%	22.1%	21%	4%	32.4%
Return on equity %	—	—	26.9%	15.5%	15.2%	15.2%	15.5%	13.9%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	43.85%	43.85%	43.85%	43.87%	43.87%	43.87%	43.87%	43.87%	43.87%	43.87%	43.87%	43.87%
	15.07%	15.56%	15.57%	18.6%	21.31%	21.96%	22.2%	19.88%	16.92%	8.12%	16.76%	17.47%
	4.02%	4.76%	5.17%	3.75%	4.1%	4.3%	4.56%	5.5%	5.28%	5.91%	6.57%	6.19%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	37.06%	35.83%	35.41%	33.78%	30.72%	29.87%	29.37%	30.75%	33.93%	42.1%	32.8%	32.47%
No. of shareholders	—	—	—	—	—	—	—	—	2,65,788	2,55,153	2,46,279	2,46,635

Promoter holding up 0.02 percentage points since Sep 2023.

22 deals · 15 Apr 2024 – 12 Aug 2026

Date	Client	Type	Venue	Side	Quantity	Price	Value
12 Aug 2026	MICROCURVES TRADING PRIVATE LIMITED	Bulk	NSE	Sell	43,49,697	₹313.40	₹136.32 Cr
12 Aug 2026	MICROCURVES TRADING PRIVATE LIMITED	Bulk	NSE	Buy	43,49,697	₹313.24	₹136.25 Cr
28 Jul 2025	UNIFI CAPITAL PRIVATE LIMITED	Bulk	BSE	Buy	72,41,309	₹231.50	₹167.64 Cr
11 Jun 2025	ORBIMED ASIA IV MAURITIUS FVCI LIMITED	Bulk	NSE	Sell	1,02,73,443	₹249.95	₹256.78 Cr
11 Jun 2025	ORBIMED ASIA IV MAURITIUS FVCI LIMITED	Block	NSE	Sell	1,02,73,443	₹249.95	₹256.78 Cr
11 Jun 2025	UNIFI CAPITAL PRIVATE LIMITED -BLENDED RANGOLI	Bulk	NSE	Buy	32,47,600	₹249.95	₹81.17 Cr
11 Jun 2025	UNIFI CAPITAL PRIVATE LIMITED -BLENDED RANGOLI	Block	NSE	Buy	32,47,600	₹249.95	₹81.17 Cr
11 Jun 2025	UNIFI BLEND FUND 2	Bulk	NSE	Buy	30,00,000	₹249.95	₹74.99 Cr
11 Jun 2025	UNIFI BLEND FUND 2	Block	NSE	Buy	30,00,000	₹249.95	₹74.99 Cr
11 Jun 2025	SOCIETE GENERALE	Block	NSE	Buy	9,20,184	₹249.95	₹23.00 Cr

1–10 of 22

1 / 3

Mr. MARK SALDANHAExecutive Director-Chairperson related to Promoter-CEO-MD
Mrs. SANDRA SALDANHAExecutive Director
Jitendra SharmaChief Finance Officer (CFO)
Mr. VARDDHMAN VIKRAMADITYA JAINExecutive Director
Mr. DIGANT MAHESH PARIKHNon-Executive - Independent Director
Mr. ABHINNA SUNDAR MOHANTYNon-Executive - Independent Director
Mrs. SHAILAJA VARDHANNon-Executive - Independent Director
Mr. SUNNY SHARMANon-Executive - Non Independent Director
Mr. SRINIVAS MISHRANon-Executive - Independent Director
Harshavardhan PanigrahiCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

Portfolio month

Schemes holding

across 5 fund houses

Held by these funds

1.15%

of the company's equity

All mutual funds

4.36%

shareholding pattern, Jun 2026

Portfolios as of

August 2026

compared with July 2026

9 schemes · 5 fund houses

		Shares
Portfolio of Kotak MNC Fund	Kotak Mahindra Mutual Fund	20 L	64.32	2.79%	0.441%	-0
Portfolio of Kotak Special Opportunities Fund	Kotak Mahindra Mutual Fund	17.6 L	56.61	3.33%	0.388%	-0
Portfolio of Kotak Healthcare Fund	Kotak Mahindra Mutual Fund	6 L	19.3	2.51%	0.132%	-0
(Investment Manager for Motilal Oswal Mutual Fund)	Motilal Oswal Mutual Fund	5.59 L	17.99	0.72%	0.123%	-12,249
Flexi Cap Fund	Old Bridge Mutual Fund	2.45 L	7.88	1.98%	0.054%	+10,000
SMALL CAP FUND	Samco Mutual Fund	42,381	1.36	0.69%	0.009%	+24,672
(Investment Manager for Motilal Oswal Mutual Fund)	Motilal Oswal Mutual Fund	5,842	0.19	0.42%	0.001%	+8
IB18-Groww Nifty Total Market Index Fund	Groww Mutual Fund	3,830	0.12	0.03%	0.001%	+18

1–8 of 9

1 / 2

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Aug 2026Transcript AI SummaryPPTREC
May 2026Transcript AI Summary PPT

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

13

Final dividend20 Aug 2026 · ex-date₹0.9
Final dividend1 Aug 2025 · ex-date₹0.8
Final dividend17 Sept 2024 · ex-date₹0.6
Final dividend7 Jun 2023 · ex-date₹0.5
Final dividend19 Aug 2022 · ex-date₹0.25
Final dividend15 Sept 2021 · ex-date₹0.25
Final dividend22 Sept 2020 · ex-date₹0.1
Final dividend19 Sept 2019 · ex-date₹0.05
Dividend dividend19 Sept 2018 · ex-date₹0.05
Dividend dividend19 Sept 2017 · ex-date₹0.05
Dividend dividend22 Sept 2016 · ex-date₹0.12
Dividend dividend23 Sept 2015 · ex-date₹0.12
Dividend dividend18 Sept 2014 · ex-date₹0.1

1

Board meeting to consider results12 Aug 2026

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

22 announcementsExport CSV

17 Sept 2026, 2:20 pmCompany Update

Special Window For Re-Lodgement Of Transfer Requests Of Physical Shares

General PDF

Loading announcements…

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	50.2%	52%	56.8%	51.9%	50.3%	52.3%	56.4%	56.7%
EBITDA margin %	13.2%	17%	24.7%	17.4%	18.3%	21.1%	20.2%	20.4%
EBIT margin %	10.9%	14.6%	22.1%	14.4%	15.5%	17.6%	17%	17%
PAT margin %	8%	10.7%	17.3%	12.5%	14.3%	14.5%	14.6%	14.2%
Working capital
Receivable days	—	—	72	97	82	76	75	80
Inventory days	—	—	248	216	192	217	270	278
Payable days	—	—	—	102	91	94	98	96
NWC days	—	—	—	211	183	199	247	261
Leverage
Current ratio	—	—	3.02	3.37	4.91	4.78	4.62	5.17
Debt to EBITDA	—	—	0.06	0.16	0.12	0.06	0.04	0.05
Debt to equity	—	—	0.02	0.03	0.02	0.01	0.01	0.01
Interest coverage	11.8	19	38.8	30.3	38	38.8	44.1	24.2
Asset turnover	—	—	1.12	0.91	0.85	0.81	0.81	0.76
Return ratios
Return on assets %	—	—	19.4%	11.4%	12.1%	11.7%	11.8%	10.9%
Return on capital employed %	—	—	33.4%	23.1%	22.1%	21%	4%	32.4%
Return on equity %	—	—	26.9%	15.5%	15.2%	15.2%	15.5%	13.9%

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Date	Category	Subject	Filing
17 Sept 2026, 2:20 pm	Company Update General	Special Window For Re-Lodgement Of Transfer Requests Of Physical Shares	PDF
7 Sept 2026, 11:17 am	Company Update Newspaper Publication	Announcement under Regulation 30 (LODR)-Newspaper Publication	PDF
1 Sept 2026, 6:21 pm	Company Update Analyst / Investor Meet	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation	PDF
27 Aug 2026, 6:57 pm	Company Update General	Voting Results Of The 34Th Annual General Meeting Of The Company	PDF
27 Aug 2026, 6:51 pm	AGM/EGM AGM	Shareholder Meeting / Postal Ballot-Scrutinizer''s Report	PDF
27 Aug 2026, 3:00 pm	AGM/EGM AGM	Shareholder Meeting / Postal Ballot-Outcome of AGM	PDF
26 Aug 2026, 4:16 pm	Company Update General	Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015	PDF
20 Aug 2026, 11:42 am	Company Update Earnings Call Transcript	Announcement under Regulation 30 (LODR)-Earnings Call Transcript	PDF

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	179	99	237	230	21	458
	-45	-42	-259	-141	-5	-248
	-15	80	198	-69	-7	-71
Net cash flow	119	137	176	21	9	139
Free cash flow	132	53	184	22	3	328
CFO / Operating profit %	52.6%	38.3%	70%	50.2%	39.1%	76.3%

Marksans Pharma Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Events

13

1

Announcements

13

1

Not in the F&O segment

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Compounded sales growth

Compounded profit growth

Return on equity

Marksans Pharma Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Events

Dividends13

Board meetings1

Announcements

Dividends13

Board meetings1

Ratio timeline

Not in the F&O segment

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Quarterly record

Bulk & block deals

Board and management

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

13

1

13

1